[7]Lown RN,Shaw BE. Beating the odds:factors implicated in the speed and availability of unrelated haematopoietic cell donor provision[J]. Bone Marrow Transplant,2013,48(2): 210-219.
[10]HIGH K A, GEORGE L A, EYSTER M E, et al. A phase 1/2 trial of investigational Spk-8011 in hemophilia a demonstrates durable expression and prevention of bleeds [J]. Blood,2018,132(Supplement 1):487
[11]Frangoul H, Altshuler D, Cappellini MD, et al.CRISPRCas9 gene editing for sickle cell disease andβthalassemia[J]. N Engl J Med, 2021, 384(3): 252260.
[12]JUNE C H, O’CONNOR R S, KAWALEKAR O U, et al. CAR-T cell immunotherapy for human cancer [J]. Science, 2018, 359(6382):1361-5.
[13]Huang R, Li X, He Y, et al. Recent advances in CAR-T cell engineering[J]. J Hematol Oncol,2020,13(1):86.
[14]ZHAI X M，LEI R P，ZHU W，et al.Chinese bloethicists respond to the case of He Jiankui[Z].The Hastings Center，2019.
